Log in

Zai Lab News Headlines (NASDAQ:ZLAB)

$55.99
-1.83 (-3.16 %)
(As of 02/28/2020 03:10 AM ET)
Today's Range
$54.03
Now: $55.99
$57.83
50-Day Range
$40.75
MA: $54.13
$62.90
52-Week Range
$23.42
Now: $55.99
$63.95
Volume556,246 shs
Average Volume462,983 shs
Market Capitalization$3.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.34

Headlines

Zai Lab (NASDAQ ZLAB) News Headlines

Source:
DateHeadline
Zai Lab Ltd (NASDAQ:ZLAB) Receives Consensus Recommendation of "Buy" from BrokeragesZai Lab Ltd (NASDAQ:ZLAB) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 14 at 2:44 AM
Zai Lab Ltd (NASDAQ:ZLAB) Short Interest UpdateZai Lab Ltd (NASDAQ:ZLAB) Short Interest Update
www.americanbankingnews.com - February 13 at 1:22 AM
Zai Lab Announces Upcoming Participation at February ConferencesZai Lab Announces Upcoming Participation at February Conferences
finance.yahoo.com - February 11 at 8:34 AM
Zai Lab application for omadacycline accepted in ChinaZai Lab application for omadacycline accepted in China
seekingalpha.com - February 10 at 1:49 PM
Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPAZai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA
finance.yahoo.com - February 10 at 8:48 AM
Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging StudiesZai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies
finance.yahoo.com - February 4 at 9:23 AM
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe OptionZai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
finance.yahoo.com - January 27 at 6:00 PM
Zai Lab (ZLAB) Hits All-time High: Did You Ride The Rally?Zai Lab (ZLAB) Hits All-time High: Did You Ride The Rally?
www.nasdaq.com - January 26 at 2:10 PM
Zai Lab prices $261M ADS offering; shares down 2% premarketZai Lab prices $261M ADS offering; shares down 2% premarket
seekingalpha.com - January 23 at 8:31 AM
Zai Lab Announces Pricing of Public Offering of American Depositary SharesZai Lab Announces Pricing of Public Offering of American Depositary Shares
finance.yahoo.com - January 22 at 10:29 PM
Zai Lab launches equity offering; shares down 1% after hoursZai Lab launches equity offering; shares down 1% after hours
seekingalpha.com - January 21 at 9:11 PM
Zai Lab Announces Proposed Public Offering of American Depositary SharesZai Lab Announces Proposed Public Offering of American Depositary Shares
finance.yahoo.com - January 21 at 9:11 PM
Zai Lab Appoints Lonnie Moulder to Board of DirectorsZai Lab Appoints Lonnie Moulder to Board of Directors
finance.yahoo.com - January 14 at 8:25 AM
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric CancerZai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
finance.yahoo.com - January 9 at 4:33 PM
Week In Review: Geneseeq And Elpiscience Close $100 Million VC Rounds; Zai Labs PARP Inhibitor Approved For China UseWeek In Review: Geneseeq And Elpiscience Close $100 Million VC Rounds; Zai Lab's PARP Inhibitor Approved For China Use
seekingalpha.com - December 31 at 1:22 AM
How Does Zai Lab Limited (NASDAQ:ZLAB) Affect Your Portfolio Volatility?How Does Zai Lab Limited (NASDAQ:ZLAB) Affect Your Portfolio Volatility?
finance.yahoo.com - December 30 at 10:18 AM
Zai Labs NDA for Zeluja for recurrent ovarian cancer OKd in ChinaZai Lab's NDA for Zeluja for recurrent ovarian cancer OK'd in China
seekingalpha.com - December 27 at 10:30 PM
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian CancerZai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
finance.yahoo.com - December 27 at 12:26 PM
Benzinga Pros Top 5 Stocks To Watch For Fri., Dec. 27, 2019: NKE, AXE, PT, FLXN, ZLABBenzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 27, 2019: NKE, AXE, PT, FLXN, ZLAB
finance.yahoo.com - December 27 at 12:26 PM
Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare ConferenceZai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 23 at 8:07 AM
Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory BoardZai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board
finance.yahoo.com - December 16 at 12:28 PM
Hedge Funds Have Never Been This Bullish On Zai Lab Limited (ZLAB)Hedge Funds Have Never Been This Bullish On Zai Lab Limited (ZLAB)
finance.yahoo.com - December 8 at 11:00 PM
The Daily Biotech Pulse: Cassava Gains On Alzheimers Presentation, Bristol-Myers Hikes DividendThe Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
feeds.benzinga.com - December 6 at 8:16 AM
Buy These 2 Stocks to Access Chinas Huge Healthcare MarketBuy These 2 Stocks to Access China's Huge Healthcare Market
www.fool.com - November 6 at 8:27 AM
Five Prime Restructuring Puts It Into A Better PositionFive Prime Restructuring Puts It Into A Better Position
seekingalpha.com - October 31 at 6:13 PM
Zai Lab Announces Upcoming Presentations at November ConferencesZai Lab Announces Upcoming Presentations at November Conferences
finance.yahoo.com - October 30 at 7:59 AM
Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction CancerZai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
finance.yahoo.com - October 25 at 12:39 PM
Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) forZai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for
www.bloomberg.com - October 24 at 8:40 AM
Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian CancerZai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
finance.yahoo.com - October 24 at 8:40 AM
Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO ConferenceDr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference
finance.yahoo.com - October 4 at 2:34 PM
BRIEF-Zai Lab Announces Phase 3 PRIMA trial of Zejula(niraparib)BRIEF-Zai Lab Announces Phase 3 PRIMA trial of Zejula(niraparib)
www.msn.com - September 29 at 9:37 PM
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardlessPhase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless
www.bloomberg.com - September 29 at 3:49 PM
Should Zai Lab (NASDAQ:ZLAB) Be Disappointed With Their 93% Profit?Should Zai Lab (NASDAQ:ZLAB) Be Disappointed With Their 93% Profit?
finance.yahoo.com - September 13 at 9:38 AM
Zai Lab Limited (ZLAB) Q2 2019 Earnings Call TranscriptZai Lab Limited (ZLAB) Q2 2019 Earnings Call Transcript
finance.yahoo.com - September 4 at 12:11 PM
Zai Lab out with 1H NumbersZai Lab out with 1H Numbers
www.baystreet.ca - September 3 at 10:51 AM
Zai Lab Ltd. to Host Earnings CallZai Lab Ltd. to Host Earnings Call
finance.yahoo.com - September 3 at 10:51 AM
Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019
finance.yahoo.com - September 3 at 10:51 AM
BRIEF-Zai Lab Announces Publication Of Pharmacokinetic Study Of Niraparib In Chinese Ovarian Cancer PatientsBRIEF-Zai Lab Announces Publication Of Pharmacokinetic Study Of Niraparib In Chinese Ovarian Cancer Patients
www.msn.com - August 27 at 10:58 PM
Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer PatientsZai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients
finance.yahoo.com - August 27 at 10:19 AM
Zai Lab Announces Upcoming Presentations at September ConferencesZai Lab Announces Upcoming Presentations at September Conferences
finance.yahoo.com - August 26 at 10:15 AM
Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019
finance.yahoo.com - August 20 at 8:10 AM
Week In Review: Chipscreen Gains 367% Following $148 Million Shanghai STAR IPOWeek In Review: Chipscreen Gains 367% Following $148 Million Shanghai STAR IPO
seekingalpha.com - August 18 at 5:08 PM
Zai Lab up 7% accelerated review status for Optune in ChinaZai Lab up 7% accelerated review status for Optune in China
seekingalpha.com - August 13 at 6:15 PM
Zai Lab, Recent GIST Hype And HER2 Turmoil Revealed An Excellent Short-Selling OpportunityZai Lab, Recent GIST Hype And HER2 Turmoil Revealed An Excellent Short-Selling Opportunity
seekingalpha.com - July 5 at 5:04 PM
Here is What Hedge Funds Think About Zai Lab Limited (ZLAB)Here is What Hedge Funds Think About Zai Lab Limited (ZLAB)
finance.yahoo.com - July 5 at 5:04 PM
Incyte teams up with Zai Lab in Greater ChinaIncyte teams up with Zai Lab in Greater China
seekingalpha.com - July 2 at 9:49 AM
China biotech groups spend billions on overseas drug candidatesChina biotech groups spend billions on overseas drug candidates
finance.yahoo.com - June 24 at 5:44 PM
Zai Lab: A Pearl In The Healthcare MarketZai Lab: A Pearl In The Healthcare Market
seekingalpha.com - June 19 at 11:32 AM
Zai Lab gets nod in Macau to sell Zejula for ovarian cancerZai Lab gets nod in Macau to sell Zejula for ovarian cancer
seekingalpha.com - June 12 at 1:02 PM
Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian CancerZai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer
finance.yahoo.com - June 12 at 1:02 PM
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel